Does therapeutic reference pricing always result in cost-containment?: The Hungarian evidence
Authors:
- Zoltán KalóZKZoltán Kaló
- Noémi MuszbekNMNoémi Muszbek
- József BodrogiJBJózsef Bodrogi
- Judit BidlóJBJudit Bidló
- 31 March 2007
- journal article
- Published by Elsevier in Health Policy
- Vol. 80 (3) , 402-412
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British ColumbiaHealth Economics, 2006
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 2005
- Suboptimal choices and dosing of statins at start of therapyBritish Journal of Clinical Pharmacology, 2005
- Pharmaceutical policy in Italy: towards a structural change?Health Policy, 2005
- Drug Insurance Utilization Management Policies and “Reference Pricing”: An Illustrated Commentary on the Article by Vittorio Maio and ColleaguesThe Milbank Quarterly, 2005
- Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockersClinical Pharmacology & Therapeutics, 2003
- Reference Pricing For Drugs: Is It Compatible With U.S. Health Care?Health Affairs, 2003
- Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS)American Heart Journal, 2002
- Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme InhibitorsNew England Journal of Medicine, 2002
- Increased thrombotic vascular events after change of statinThe Lancet, 1998